ClinicalTrials.gg
RecruitingNCT06001606Updated Aug 21, 2023

Immunogenicity, Reactogenicity of Shingrix in SLE

A Phase 3 interventional study of Shingrix and Placebo in Zoster, Systemic Lupus Erythematosus and Vaccine Reaction, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Seoul National University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
40th of 46
63 · median 239
Started
2023
with 5 others
Phase 3
22 of 46
2 open now
Primary completion
2025-04
later than 2 of 10 live
Registered
40th of 46
by date

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 40th largest by planned enrollment, is one of 6 that started in 2023, is one of 22 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 40th registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.

03

Conditions studied

  • Zoster
  • Systemic Lupus Erythematosus
  • Vaccine Reaction
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥ 19 years of age at time of consent
  • ≥4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (13, 14)
  • Clinically stable SLE
  • use: ≥ 5mg/day of prednisolone equivalent
  • Stable dose of one or more of the following treatment ≥ 4 weeks

    • Antimalarials (≤400 mg/day)
    • Azathioprine (≤3 mg/kg/day)
    • Mycophenolate mofetil (≤3 mg/day)
    • Tacrolimus (≤5mg/day)
    • Methotrexate (≤20mg/week)
    • Cyclosphosphamide (≤1mg/BSA/month)
  • Must understand and voluntarily sign an form including writing consent for data protection

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Acute infection with T >38°C at the time of vaccination
  • Previous anaphylactic response to vaccine components or to egg
  • History of Guillain-Barre syndrome or demyelinating syndromes
  • Any condition including laboratory abnormality which places the subject at unacceptable risk
  • Subjects who decline to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (estimated)

Study arms

  • Experimental
    Shingrix

    Drug: Shingrix

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Shingrix vaccination

  • DrugPlacebo

    Placebo vaccination

06

What researchers measure

Primary outcomes

  1. Frequency of positive humoral vaccine response at 1 month post-dose 2

    Proporition of pariticpants who achieved a ≥4-fold increase in the anti-gE antibody concentration as compared to the prevaccination concentration

    Time frame: 3 months

Secondary outcomes

  1. Frequency of positive humoral vaccine response at 6 months post-dose 2

    Time frame: 8 months

  2. Frequency of humoral responses 12 month post-dose 2

    Time frame: 14 month

  3. Anti-gE antibody concentration at 6 months post-dose 2

    Time frame: 8 months

  4. Anti-gE antibody concentration at 12 months post-dose 2

    Time frame: 14 months

Other outcomes

  1. SLE flare rate

    Time frame: up to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Park JK, Lee YJ, Shin K, Kang EH, Ha YJ, Park JW, Kim MJ, Kim MH, Choi SR, Jung Y, Lee JH, In Jung J, Kim JY, Winthrop KL, Lee EB. A Multicenter, Prospective, Randomized, Parallel-Group Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2023 Feb;75(2):171-177. doi: 10.1002/art.42318. Epub 2022 Dec 7. PubMed 35930728 ↗
  • Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017 Sep;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128. Epub 2017 May 3. PubMed 28468794 ↗
  • Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222. Epub 2018 Mar 23. PubMed 29572291 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2025, 23 months after the start.

Of 40 phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
Aug 21, 2023
StartActual
May 8, 2023
Primary completionEst.
Apr 24, 2025
CompletionEst.
Apr 24, 2025
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06001606
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
May 8, 2023
Primary completion
Apr 24, 2025 (estimated)
Completion
Apr 24, 2025 (estimated)
Last update
Aug 21, 2023

Study contacts

Jin Kyun Park, MD
Contact
jinkyunpark@snu.ac.kr
82-2-2072-4765

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion